Subscribe to RSS
DOI: 10.1055/s-0043-1766093
2023 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles
![](https://www.thieme-connect.de/media/sth/202305/lookinside/thumbnails/10-1055-s-0043-1766093_03114-1.jpg)
Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2023 represents 15 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:
![](https://www.thieme-connect.de/media/sth/202305/thumbnails/10-1055-s-0043-1766093-i03114-1.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
-
➢ Most popular article awards: Awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the editor in chief on the basis of user statistics from Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles and another for a “General Category.” There are two major cash prizes of US$ 1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.
-
➢ Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen (up to six cash prizes of US$ 1,000 in any year). There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other article related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the current coronavirus disease 2019 (COVID-19) pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.
Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1]).
It is therefore with great pleasure that we would like to announce the latest winners of the 2023 Eberhard F. Mammen awards for the most popular articles from STH, as downloaded in 2022 and as published in the period of 2021–2022 inclusive.
Publication History
Article published online:
20 March 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Allaoui A, Khawaja AA, Badad O. et al. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021; 47 (04) 419-426
- 2 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
- 3 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
- 4 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021; 47 (04) 372-391
- 5 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
- 6 Abate V, Casoria A, Rendina D. et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; 48 (01) 100-108
- 7 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
- 8 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021; 47 (04) 400-418
- 9 Fernández-Capitán C, Barba R, Díaz-Pedroche MDC. et al. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021; 47 (04) 351-361
- 10 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
- 11 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
- 12 Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost 2021; 47 (04) 392-399
- 13 Hvas CL, Larsen JB, Adelborg K, Christensen S, Hvas AM. Dynamic hemostasis and fibrinolysis assays in intensive care COVID-19 patients and association with thrombosis and bleeding - a systematic review and a cohort study. Semin Thromb Hemost 2022; 48 (01) 31-54
- 14 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022; 48 (04) 446-458
- 15 Leiderman K, Sindi SS, Monroe DM, Fogelson AL, Neeves KB. The art and science of building a computational model to understand hemostasis. Semin Thromb Hemost 2021; 47 (02) 129-138
- 16 Branstetter JW, Kiskaddon AL, King MA. et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in pediatric venous thromboembolism treatment and thromboprophylaxis: a systematic review of the literature. Semin Thromb Hemost 2021; 47 (06) 643-653
- 17 Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022; 48 (02) 206-218
- 18 Thachil J. Protamine - the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost 2022; 48 (02) 240-243
- 19 Liesdek OCD, Urbanus RT, de Heer LM, Fischer K, Suyker WJL, Schutgens REG. Alternatives for vitamin K antagonists as thromboprophylaxis for mechanical heart valves and mechanical circulatory support devices: a systematic review. Semin Thromb Hemost 2021; 47 (06) 724-734
- 20 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
- 21 Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021; 47 (07) 759-774
- 22 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
- 23 Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022; 48 (05) 514-528
- 24 Ichinose A, Osaki T, Souri M, Favaloro EJ. A review of autoimmune acquired von Willebrand factor deficiency in Japan. Semin Thromb Hemost 2022; 48 (08) 911-925
- 25 Carpenè G, Negrini D, Lippi G, Favaloro EJ, Montagnana M. Heparin: the journey from parenteral agent to nasal delivery. Semin Thromb Hemost 2022; 48 (08) 949-954
- 26 Christiansen M, Grove EL, Hvas AM. Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives. Semin Thromb Hemost 2021; 47 (07) 800-814
- 27 Aamodt AH, Skattør TH. Cerebral venous thrombosis. Semin Thromb Hemost 2022; 48 (03) 309-317
- 28 Kjaergaard AB, Fuglsang J, Hvas AM. Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review. Semin Thromb Hemost 2021; 47 (07) 824-842
- 29 Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost 2022; 48 (05) 596-606
- 30 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
- 31 Favaloro EJ. 2020 Eberhard F. Mammen Award announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2021; 47 (03) 229-237
- 32 Favaloro EJA. 2018 Update on the editorial and publication policy of Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 33 Favaloro EJ. 2022 Eberhard F. Mammen Award announcements: Part I - most popular articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 34 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part I. Semin Thromb Hemost 2020; 46 (07) 757-762
- 35 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): Part II. Semin Thromb Hemost 2021; 47 (04) 333-337
- 36 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part III. Semin Thromb Hemost 2022; 48 (01) 3-7
- 37 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
- 38 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the Multicenter Italian CORIST Study. Thromb Haemost 2021; 121 (08) 1054-1065
- 39 Italian Medicines Agency. Uso delle eparine nei pazienti adulti con COVID-19. Accessed February 11, 2023 at: https://www.aifa.gov.it/documents/20142/0/Eparine_Basso_Peso_Molecolare_13.05.2021.pdf